Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.02 – $1.14
Volume15,697
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.73M
Price / earnings
—
Price / book
3.48×
Price / sales
—
EV / sales
—
EV / EBITDA
0×
Profitability
Earnings per share
-$8.52
Return on assets
-742.59%
Return on equity
-2,768.93%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
1.36×
Quick ratio
1.36×
Cash ratio
1.3×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SKYE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.66M
$3.87M
$4.74M
$3.43M
$3.91M
$3.91M
$4.56M
$4.55M
Research and development
$1.32M
$3.94M
$7.94M
$11.47M
$9.36M
$14.34M
$7.2M
$7.79M
Total operating expenses
-$26.32K
$11.06M
$12.67M
$14.9M
$13.26M
$18.24M
$11.76M
$10.67M
Operating income
$26.32K
-$11.06M
-$12.67M
-$14.9M
-$13.26M
-$18.24M
-$11.76M
-$10.67M
Interest expense
-$3.3K
-$3.3K
-$2.2K
$0
$0
$0
-$1.45K
$46.91K
Income before taxes
$69.13K
-$10.78M
-$12.51M
-$14.44M
-$12.75M
-$17.62M
-$11.1M
-$9.75M
Income taxes
$0
$3.4K
$0
$0
$0
$3.4K
$2K
$0
Net income
$69.13K
-$10.79M
-$12.51M
-$14.44M
-$12.75M
-$17.62M
-$11.1M
-$9.75M
Net income attributable to common shareholders
$69.13K
-$10.79M
-$12.51M
-$14.44M
-$12.75M
-$17.62M
-$11.1M
-$9.75M
EBITDA
$57.64K
-$10.9M
-$12.5M
-$14.72M
-$13.09M
-$18.06M
-$11.58M
-$10.49M
Basic earnings per share
$0.01
-$2.16
-$2.56
-$2.91
-$2.57
-$3.52
-$2.24
-$1.93
Diluted earnings per share
$0.01
-$2.16
-$2.56
-$2.91
-$2.57
-$3.52
-$2.24
-$1.93
Recent news
Company coverage with links to the original publishers.
Skye Bioscience presented preclinical data on nimacimab, a CB1 receptor inhibitor antibody, showing significant additive weight loss effects when combined with tirzepatide and semaglutide in diet-induced obesity mouse models. The drug demonstrated durable weight loss after treatment discontinuation and reduced weight rebound by ~80% when used as maintenance therapy post-tirzepatide discontinuation. Skye is currently conducting a Phase 2a clinical trial combining nimacimab with GLP-1R agonists.
Levi & Korsinsky has filed a securities class action lawsuit against Skye Bioscience, Inc. on behalf of shareholders who suffered losses between November 4, 2024 and October 3, 2025. The complaint alleges that defendants made false statements about the effectiveness of the company's lead product candidate, nimacimab, and overstated its clinical, regulatory, and commercial prospects. Investors who suffered losses during this period can request to be appointed as lead plaintiff by January 16, 2026.
Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects.
Rosen Law Firm is reminding investors in Jayud Global Logistics Ltd. (JYD), Skye Bioscience, Inc. (SKYE), and Klarna Group plc (KLAR) of upcoming lead plaintiff deadlines in securities class action lawsuits. The firm is encouraging affected investors to secure legal counsel to potentially recover losses from alleged fraudulent activities and misleading statements.
Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.